Charles Schwab’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.1M | Sell |
941,285
-4,471
| -0.5% | -$57K | ﹤0.01% | 2013 |
|
|
2025
Q4 | $8.5M | Buy |
945,756
+72,568
| +8% | +$999K | ﹤0.01% | 2212 |
|
|
2025
Q3 | $15.1M | Buy |
873,188
+16,639
| +2% | +$205K | ﹤0.01% | 1903 |
|
|
2025
Q2 | $8.03M | Buy |
856,549
+76,325
| +10% | +$627K | ﹤0.01% | 2118 |
|
|
2025
Q1 | $5.55M | Sell |
780,224
-7,266
| -0.9% | -$73.4K | ﹤0.01% | 2226 |
|
|
2024
Q4 | $9.18M | Sell |
787,490
-40,055
| -5% | -$625K | ﹤0.01% | 2056 |
|
|
2024
Q3 | $17M | Buy |
827,545
+37,714
| +5% | +$870K | ﹤0.01% | 1780 |
|
|
2024
Q2 | $17.7M | Buy |
789,831
+61,536
| +8% | +$1.47M | ﹤0.01% | 1751 |
|
|
2024
Q1 | $20M | Buy |
728,295
+28,067
| +4% | +$780K | ﹤0.01% | 1609 |
|
|
2023
Q4 | $21.3M | Buy |
700,228
+18,987
| +3% | +$546K | 0.01% | 1566 |
|
|
2023
Q3 | $21.5M | Sell |
681,241
-271,476
| -28% | -$10.5M | 0.01% | 1463 |
|
|
2023
Q2 | $38.9M | Buy |
952,717
+83,545
| +10% | +$3.39M | 0.01% | 1035 |
|
|
2023
Q1 | $32.4M | Sell |
869,172
-23,459
| -3% | -$920K | 0.01% | 1132 |
|
|
2022
Q4 | $31.1M | Buy |
892,631
+120,656
| +16% | +$5.74M | 0.01% | 1126 |
|
|
2022
Q3 | $43.2M | Buy |
771,975
+58,530
| +8% | +$3.63M | 0.02% | 852 |
|
|
2022
Q2 | $36.9M | Buy |
713,445
+17,078
| +2% | +$867K | 0.01% | 958 |
|
|
2022
Q1 | $50.6M | Buy |
696,367
+14,446
| +2% | +$1.22M | 0.02% | 864 |
|
|
2021
Q4 | $80.6M | Buy |
681,921
+15,099
| +2% | +$1.89M | 0.02% | 633 |
|
|
2021
Q3 | $89.5M | Buy |
666,822
+209,525
| +46% | +$31.7M | 0.03% | 544 |
|
|
2021
Q2 | $74M | Buy |
457,297
+26,081
| +6% | +$2.03M | 0.02% | 632 |
|
|
2021
Q1 | $34.6M | Buy |
431,216
+60,783
| +16% | +$4.08M | 0.01% | 1089 |
|
|
2020
Q4 | $20.2M | Buy |
370,433
+28,691
| +8% | +$1.04M | 0.01% | 1401 |
|
|
2020
Q3 | $6.79M | Buy |
341,742
+40,937
| +14% | +$854K | ﹤0.01% | 1915 |
|
|
2020
Q2 | $6.32M | Buy |
300,805
+53,927
| +22% | +$916K | ﹤0.01% | 1909 |
|
|
2020
Q1 | $3.02M | Buy |
246,878
+2,683
| +1% | +$36.1K | ﹤0.01% | 2084 |
|
|
2019
Q4 | $3.58M | Buy |
244,195
+5,695
| +2% | +$79.2K | ﹤0.01% | 2194 |
|
|
2019
Q3 | $3.18M | Buy |
238,500
+42,290
| +22% | +$674K | ﹤0.01% | 2198 |
|
|
2019
Q2 | $3.21M | Buy |
196,210
+13,205
| +7% | +$208K | ﹤0.01% | 2179 |
|
|
2019
Q1 | $3.13M | Buy |
183,005
+11,387
| +7% | +$170K | ﹤0.01% | 2202 |
|
|
2018
Q4 | $2.34M | Sell |
171,618
-2,144
| -1% | -$39.9K | ﹤0.01% | 2276 |
|
|
2018
Q3 | $4.97M | Buy |
173,762
+43,654
| +34% | +$1.27M | ﹤0.01% | 2044 |
|
|
2018
Q2 | $3.56M | Buy |
130,108
+38,723
| +42% | +$938K | ﹤0.01% | 2164 |
|
|
2018
Q1 | $1.93M | Buy |
91,385
+12,256
| +15% | +$301K | ﹤0.01% | 2347 |
|
|
2017
Q4 | $1.52M | Buy |
79,129
+21,637
| +38% | +$500K | ﹤0.01% | 2398 |
|
|
2017
Q3 | $1.43M | Buy |
57,492
+14,818
| +35% | +$279K | ﹤0.01% | 2409 |
|
|
2017
Q2 | $683K | Buy |
42,674
+15,771
| +59% | +$220K | ﹤0.01% | 2590 |
|
|
2017
Q1 | $380K | Buy |
26,903
+1,539
| +6% | +$20.7K | ﹤0.01% | 2740 |
|
|
2016
Q4 | $333K | Buy |
25,364
+1,386
| +6% | +$20.8K | ﹤0.01% | 2810 |
|
|
2016
Q3 | $409K | Buy |
23,978
+1,224
| +5% | +$23.7K | ﹤0.01% | 2688 |
|
|
2016
Q2 | $486K | Buy |
+22,754
| New | +$605K | ﹤0.01% | 2597 |
|
Other funds holding NTLA
AIM
VPM
VCM
RP
